BioRestorative Therapies Inc.

05/01/2026 | Press release | Distributed by Public on 05/01/2026 14:18

Management Change/Compensation (Form 8-K)

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(f)
On May 1, 2026, the Compensation Committee of the Board of Directors of BioRestorative Therapies, Inc. (the "Company") approved cash bonuses for the Company's executive officers for the year ended December 31, 2025, as set forth below in the updated Summary Compensation Table.
Summary Compensation Table
The following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31, 2025 and 2024 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal executive officer, who were serving as an executive officer as of December 31, 2025 and whose total compensation for the 2025 fiscal year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively referred to as the Named Executive Officers):
Name and Principal Position
Year
Salary
Bonus
Stock Awards(1)
Option Awards(1)
All Other Compensation
Total
Lance Alstodt
2025
$
596,666
$
300,000
(2)
$
-
$
1,512,500
$
-
$
2,409,167
Chief Executive Officer
2024
$
539,583
$
275,000
(3)
$
-
$
500,000
$
-
$
1,314,583
Francisco Silva
2025
$
566,666
$
287,500
(2)
-
$
1,468,750
-
$
2,322,916
VP, Research and Development
2024
$
514,583
$
262,500
(3)
$
-
$
450,000
$
-
$
1,227,083
Robert Kristal
2025
$
343,750
$
140,000
(2)
$
-
$
318,000
$
-
$
801,750
Chief Financial Officer
2024
$
293,752
$
90,000
(3)
$
-
$
300,000
$
-
$
683,752
(1)
Amounts reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 6 to our consolidated financial statements included in this Annual Report.
(2)
The 2025 Bonus amount represents a discretionary bonus in consideration of 2025 services which is to be paid in 2026.
(3)
The 2024 Bonus amount represents a discretionary bonus in consideration of 2024 services which was paid in 2025.

BioRestorative Therapies Inc. published this content on May 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 01, 2026 at 20:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]